ClinicalTrials.gov
public full text
Public Domain
Study of N91115 in Patients With Cystic Fibrosis Homozygous F508del-CFTR Mutation
This Phase 1b study in F508del-CFTR homozygous CF patients is being conducted to assess the safety of N91115 as the sole cystic fibrosis transmembrane conductance regulator (CFTR) modulator at doses near the expected therapeutic exposure level in preparation for Phase 2 studies of N91115 added to the CFTR modulator combination lumacaftor/ivacaftor when launched.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Utilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver Progression#1047587
- 42 CFR Part 73 — Select Agents and Toxins#509928
- 21 CFR Part 660 — Additional Standards for Diagnostic Substances for Laboratory Tests#506876
- 21 CFR Part 866 — Immunology and Microbiology Devices#506901
- 21 CFR Part 610 — General Biological Products Standards#506873
Record · ID 862305
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive